The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s leukemia therapeutics market report forecasts the leukemia therapeutics market size to grow to $21.57 Billion by 2027, with a CAGR (compound annual growth rate) of more than 7%.

Learn More On The Leukemia Therapeutics Market Report 2023 – https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Leukemia Therapeutics Market Size Forecast
The global leukemia therapeutics market is expected to grow from $15.16 billion in 2022 to $16.25 billion in 2023 at a compound annual growth rate (CAGR) of 7.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The leukemia therapeutics market size is expected to grow to $21.57 billion in 2027 at a CAGR of 7.3%.

North America held the largest leukemia therapeutics market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Leukemia Therapeutics Market Driver ­– Rise In The Prevalence Of Leukemia
For instance, according to the National Cancer Institute, the number of new leukemia cases in the United States increased from 60,530 cases in 2020 to 61,090 cases in 2021. Therefore, the rising prevalence of leukemia is contributing to the growth of the leukemia therapeutics market.

Request for A Sample Of The Global Leukemia Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6358&type=smp

Key Leukemia Therapeutics Market Trend – Adopting Combination Therapies
In combination therapies, two or more modalities are tested in combinations with other immunotherapies or targeted therapies that promise to deliver long-term survival benefits that may be unavailable with current approaches. For instance, in September 2021, Dana-Farber Cancer Institute, a US-based cancer treatment, and research institute’s clinical research team reported that a combination of three molecularly targeted drugs including an inhibitor of BCL-2 (venetoclax), a second-generation inhibitor of BTK (acalabrutinib), and a CD20 inhibitor (obinutuzumab) are effective against chronic lymphocytic leukemia (CLL).

Leukemia Therapeutics Market Segment
1) By Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments
2) By Type Of Leukemia: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Type Of Leukemia
3) By Molecule Type: Small Molecules, Biologics
4) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Leukemia Therapeutics Market Major Players and Strategies
Major players in the leukemia therapeutics market are Novartis International AG, AbbVie, Bristol Myers Squibb, F. Hoffmann-La Roche AG, Sanofi S.A., Pfizer Inc., Amgen Inc., Takeda Pharmaceutical, Celgene Corporation, GlaxoSmithKline plc, Exelixis Inc., MorphoSys AG, Otsuka Holdings Company Ltd., and Lupin Ltd.

In November 2021, Pfizer Inc., a US-based pharmaceutical company, acquired Trillium Therapeutics for approximately $2.22 billion. With this acquisition, Pfizer aims to boost its oncology portfolio with the addition of next-generation immunotherapies from Trillium. Trillium Therapeutics is a Canada-based clinical-stage immuno-oncology company developing therapies for the treatment of cancer.

The Leukemia Therapeutics Global Market Report 2023 covers regional data on leukemia therapeutics market size, leukemia therapeutics market trends and drivers, opportunities, strategies, and leukemia therapeutics market competitor analysis. The countries covered in the leukemia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Leukemia therapeutics refer to a treatment used to treat an aggressive (quickly spreading) malignancy in which the blood or bone marrow contain an excessive amount of myeloblasts (immature white blood cells). The type treatment for leukemia depends on various factors such as age, overall health, type of leukemia, its current condition within the body and others.

View More Reports Related To The Leukemia Therapeutics Market –
Acute Myeloid Leukemia Global Market Report 2023
Antisense & RNAi Therapeutics Global Market Report 2023
Bipolar Disorder Therapeutics Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: